HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Tan Sheet

Executive Summary

Diabetes supplement: Diabco Life Sciences launches nutraceutical with natural ingredients that have been "clinically documented and scientifically reported to help lower blood glucose levels," Carmel, Ind.-based firm says. Diabatrol is a "nutrient-dense, fiber and antioxidant-rich dietary supplement that has been scientifically proven to stabilize blood sugar spiking and reduce insulin resistance, two conditions that most often lead to Type II diabetes," the firm says. Diabatrol is a powder to be mixed with a low-sugar liquid, taken twice daily. A 60 packet one-month supply is sold online for $59.99, but the firm plans to bring the product into the retail channel soon. Ingredients include stabilized rice bran derivatives, rice protein concentrate, natural vanilla flavor, CMC gum, vitamins, mineral supplement, and aspartame...

You may also be interested in...



Natrol Pumps Up In Sports Nutrition Market With MRI Acquisition

Dietary supplement manufacturer Natrol expands its sports nutrition product offerings with its $8 million cash acquisition of Medical Research Institute

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS138324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel